US firm launches vision-restoring implant with EU approval
The implant restored central vision in 84% of 38 trial patients, and the company said it will begin sales across 30 European countries.
- Science Corporation won European regulatory approval for Prima, a device designed to restore functional central vision in patients with geographic atrophy caused by age-related macular degeneration .
- The 2x2 mm wireless implant replaces damaged photoreceptors, addressing a leading cause of permanent blindness that affects more than 5 million people worldwide.
- Clinical trial data from 38 patients across 17 sites showed 84% reported restored functional central vision, with one participant improving by 59 letters on a standard eye chart.
- With CE marking secured, the device can be sold across 30 European countries, and the first commercial implant is expected in Germany soon.
- CEO Max Hodak stated that a successful vision business provides capital for long-term bio-hybrid brain-computer interface development, positioning Prima as a revenue engine for Science Corporation's broader ambitions.
21 Articles
21 Articles
One company received approval to sell a device, called PRIMA, which restores age-related vision for macular degeneration
A retina chip that restores sight goes on sale in Europe
Geographic atrophy is the worst form of age-related macular degeneration. For most people who have it, the centre of the world slowly greys out. Faces blur. Words vanish. There is no cure, only treatments that slow the loss. Now a small chip is giving some of that sight back. Science Corp, based in Alameda, California, […] This story continues at The Next Web
Science Corporation has received CE marking for Prima, an implant developed to restore functional central vision. After demonstrating promising results in clinical trials, technology may begin to reach the...
A new brain-computer implant is helping blind seniors see again, and it just got approved in Europe
Science describes PRIMA as an "investigational" retinal implant designed to combat vision loss caused by GA and AMD. For the time being, the device is commercially available only in the European market. The implant is actually part of a more complex system that includes both a subretinal photovoltaic chip and...Read Entire Article
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
